In contrast to studies conducted in the metastatic setting, Pfeiler G. et al. (2023) [25] performed a preplanned BMI-subgroup analysis of the PALLAS trial, evaluating the impact of BMI in patients with early-stage HR+/HER2− BC receiving adjuvant ET with or without palbociclib. This evidence concerns the gene HR and breast cancer.